Zentalis Pharmaceuticals Inc. (ZNTL) Social Stream
ZENTALIS PHARMACEUTICALS INC (ZNTL) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering ZNTL.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-02 | 8 | $120 | $80 | $92.875 | $13.88 | 569.13% |
| 2021-11-11 | 8 | $120 | $84 | $98.375 | $13.88 | 608.75% |
| 2021-12-10 | 8 | $120 | $88 | $99 | $13.88 | 613.26% |
| 2021-12-17 | 8 | $120 | $88 | $101.25 | $13.88 | 629.47% |
| 2022-01-20 | 7 | $120 | $89 | $102 | $13.88 | 634.87% |
| 2022-01-31 | 7 | $120 | $89 | $100.75 | $13.88 | 625.86% |
| 2022-02-08 | 7 | $120 | $78 | $98.375 | $13.88 | 608.75% |
| 2022-02-25 | 8 | $120 | $78 | $98.375 | $13.88 | 608.75% |
| 2022-03-29 | 8 | $120 | $71 | $96.125 | $13.88 | 592.54% |
| 2022-04-11 | 9 | $120 | $67 | $92.888 | $13.88 | 569.22% |
| 2022-05-05 | 9 | $120 | $67 | $85.7 | $13.88 | 517.44% |
| 2022-05-10 | 8 | $120 | $51 | $82.666 | $13.88 | 495.58% |
| 2022-07-27 | 9 | $120 | $51 | $82.666 | $13.88 | 495.58% |
| 2022-08-09 | 9 | $120 | $51 | $82.444 | $13.88 | 493.98% |
| 2022-08-15 | 8 | $120 | $42 | $68 | $13.88 | 389.91% |
| 2022-10-26 | 7 | $120 | $42 | $68 | $13.88 | 389.91% |
| 2022-11-11 | 10 | $120 | $27 | $56.777 | $13.88 | 309.06% |
| 2023-02-07 | 10 | $120 | $27 | $52.333 | $13.88 | 277.04% |
| 2023-03-02 | 10 | $120 | $27 | $52.111 | $13.88 | 275.44% |
| 2023-05-10 | 10 | $120 | $27 | $51.111 | $13.88 | 268.23% |
| 2023-05-11 | 10 | $120 | $27 | $50.777 | $13.88 | 265.83% |
| 2023-05-25 | 10 | $70 | $27 | $45.222 | $13.88 | 225.81% |
| 2023-06-06 | 10 | $70 | $27 | $46 | $13.88 | 231.41% |
| 2023-07-26 | 10 | $70 | $28 | $47.666 | $13.88 | 243.41% |
| 2023-08-10 | 10 | $70 | $28 | $47 | $13.88 | 238.62% |
| 2023-09-20 | 10 | $70 | $28 | $47.444 | $13.88 | 241.82% |
| 2023-10-24 | 10 | $70 | $37 | $49.333 | $13.88 | 255.43% |
| 2023-11-06 | 10 | $70 | $37 | $49.333 | $13.88 | 255.43% |
| 2023-11-07 | 10 | $50 | $15 | $40 | $13.88 | 188.18% |
| 2023-11-09 | 10 | $50 | $12 | $34.777 | $13.88 | 150.55% |
The Trend in the Analyst Price Target
Over the past 21 months, ZNTL's average price target has gone down $61.35.
ZNTL reports an average of 140.39% for its upside potential over the past 39 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-05-19 | 10 | 70 | 27 | 45.222 | 26.35 | 71.62% |
| 2023-06-06 | 10 | 70 | 27 | 46.000 | 25.14 | 82.98% |
| 2023-08-10 | 10 | 70 | 28 | 47.444 | 26.74 | 77.43% |
| 2023-11-07 | 10 | 50 | 15 | 40.000 | 10.20 | 292.16% |
| 2023-11-09 | 10 | 50 | 12 | 34.777 | 9.97 | 248.82% |
ZNTL Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.4 | 8 | 0 | 2 | 0 | 0 | 10 |
The Trend in the Broker Recommendations
ZNTL's average broker recommendation rating worsened by 0.29 over the prior 19 months.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- In terms of how ZENTALIS PHARMACEUTICALS INC fares relative to all US stocks, note that its upside potential (average analyst target price relative to current price) is greater than 3231.44% of that group.
- In the context of all US stocks, ZENTALIS PHARMACEUTICALS INC's variance in analysts' estimates is lower than -2472.95% of them.
- ZNTL has a higher average analyst price target than 2701.79% of Pharmaceutical Products stocks.
- ZNTL has a higher number of analysts covering the stock than 2161.8% of stocks in the mid market cap category.
In the Pharmaceutical Products industry, SDGR, IMAB, and IGMS are the three stocks most similar to ZENTALIS PHARMACEUTICALS INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
What is the outlook for ZNTL? Use POWR Ratings for clearer insight into price direction.